Smaller companies set for third-quarter catalysts
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Evaluate Vantage's final article in a series of previews exploring key clinical readouts concerns companies with a market cap under $1bn. Previously, we outlined key catalysts for big pharma and larger biotechs that are expected to happen in the third quarter.
Travere hopes to take on a rare kidney disease with pivotal data due from the Sparsentan trial, while Radius is lining up results from its oral Serd elacestrant; comparisons could be made to imminent data from Sanofi’s more advanced amcenestrant. Elsewhere, Sio Gene is hoping a 12-month readout from its gene therapy AXO-AAV-GM1 will show durability, in the setting of GM1 gangliosidosis.
August will see data from Travere’s Sparsentan in IgA nephropathy, a rare kidney disease. The Protect study is in 380 patients, and results are due from an interim analysis of at least 280 patients after 36 weeks of treatment to evaluate the primary endpoint: change in urine protein/creatinine ratio from baseline.
The analysis is designed to support a potential submission for accelerated approval; a secondary measure, rate of change in estimated glomerular filtration rate over 58 weeks, will serve as the confirmatory endpoint.
Protect is 90% powered to detect a 30% difference in proteinuria between sparsentan and irbesartan, an angiotensis II receptor antagonist. Sparsentan is said to work by inhibiting both endothelin receptor type A and angiotensis II receptor type 1.
There are no approved therapies for IgA nephropathy but Calliditas’s Nefecon could become the first in the US with a Pdufa date of September 15 for the FDA's decision. Nefecon, an oral formulation of the steroid budesonide, showed a placebo-adjusted 27% reduction in proteinuria in phase 3 and a significant improvement in eGFR versus placebo.
Other competitors include Novartis who reported phase 2 data recently with iptacopan, an oral complement inhibitor. The high dose led to a 23% reduction in proteinuria, versus placebo, and a phase 3 study is underway.
Giving up its Serd
With the readout of Sanofi’s third-line registrational study with amcenestrant imminent, interest in oral selective oestrogen receptor degraders, or Serds, has been rising. Roche and Astrazeneca also have candidates but small biotech Radius Health is expected to report next.
Radius’s Emerald study seems to allow both second and third-line patients with ER+, Her2- breast cancer, with elacestrant monotherapy being tested against standard of care, which includes Faslodex or an aromatase inhibitor.
The co-primary endpoints are PFS in patients with oestrogen receptor 1 (ESR1) mutations and all comers. ESR1 mutation is a key resistance mechanism to endocrine therapy.
Several failures in this space means that this remains a high risk read out; Radius itself has backed away from the project, selling worldwide rights to elacestrant to Menarini for just $30m upfront last year. The deal came after Radius decided to focus on endocrine diseases, rather than oncology.
Sio Gene’s AXO-AAV-GM1 has already shown early promise at 6 months in GM1 gangliosidosis, a rare inherited lysosomal storage disorder. Next up are 12 month results from the phase 1/2 study, which will be an important test of durability, a key issue for gene therapies.
At 6 months beta-galactosidase activity was restored to, on average, 38% of normal, in five patients with juvenile or late-infantile disease. GM1 gangliosidosis patients are deficient in beta- galactosidase, leading to a build-up of toxic gangliosides in neurons and other cells.
There were also promising signs on clinical assessments including those measuring mobility, and there were no serious adverse events related to the gene therapy. Both the six month data and the upcoming 12 month results are from the low-dose cohort.
Sio is some way ahead of competitors in this disease; Passage Bio’s PBGM01 will report one month data in the fourth quarter, while the first patient was recently dosed with Lysogene’s LYS-GM101. Early next year Sio expects to report 12 month data from the first two patients treated with a higher dose.
The table below contains a fuller list of upcoming catalysts with consensus forecasts from Evaluate Pharma. Vantage has previously looked at clinical data expected for big pharma and biotech companies.
|Q3 clinical catalysts (excludes Covid-19 data)|
|Product||Company||Therapy area||Q3 clinical catalyst||2026e indication sales ($m)||Note/Vantage coverage|
|Outlook Therapeutics||Wet AMD||Pivotal Ph3 Norse Two||429||Ophthalmic formulation of Avastin, versus Lucentis|
|Rubraca||Clovis||1L ovarian cancer maintenance||Ph3 Athena, data from monotherapy arm H2||419*||Label extension, both Lynparza and Zejula are already well-entrenched in 1L ovarian cancer maintenance|
|Sparsentan||Travere Therapeutics||IgA nephropathy||Ph3 Protect due August||336||See text|
|Reproxalap ophthalmic solution||Aldeyra||Dry eye||Ph3 Tranquility, Tranquility-2 (confirmatory) H2||312||Pivotal hit in allergic conjunctivitis in April (Aldeyra eyes the future)|
|Korsuva oral||Cara||Chronic liver disease-associated pruritus||Ph2 due H2||304||Failed in atopic dermatitis, injectable version filed to treat itch in dialysis patients with August Pdufa (Cara fails to convince, but pushes on anyway)|
|EDP-305||Enanta/Undisclosed partner||Nash||Interim Argon-2 (1.5 & 2mg)||253||In Argon-1 1mg was not efficacious; 2.5mg was efficacious but caused unacceptable pruritus (Enanta fails to convince with Nash win)|
|Lenabasum||Corbus||SLE||Ph2 H2||220||Failed in systemic sclerosis, cystic fibrosis and dermatomyositis|
|STRO-002||Sutro||Ovarian cancer||Ph1 dose expansion data||187||Anti-FRα (folate receptor) MAb-drug conjugate, promising early data but issues with neutropenia (Sutro bucks the folate trend)|
|ADP-A2M4CD8||Adaptimmune||Solid tumours||Ph1 Surpass update at Esmo (Sept 17-21)||130||Next gen candidate, MAGE-A4 specific, CD8|
|XEN1101||Xenon||Adult focal seizures||Ph2b X-Tole||122||Potassium channel modulator, adjunctive treatment|
|Elacestrant||Radius/Menarini||Breast cancer ER+/Her2-||Ph3 Emerald H2||69||See text.|
|SLN360||Silence||Cardiovascular disease due to elevated lipoprotein a||Ph1 Apollo single ascending dose portion data H2||65||siRNA against apolipoprotein A, Astrazeneca signed a $80m cash-and-equity deal with Silence Therapeutics last March (Astrazeneca throws Silence an $80m lifeline)|
|Auto4||Autolous||TRBC1+ T cell lymphoma||Ph1 interim||50||Designed to treat peripheral T-cell lymphomas, where treatment options are severely limited|
|Ganaxolone (oral)||Marinus||Tuberous sclerosis complex||Ph2||39||Jazz's Epidiolex got approved in this setting last year (Marinus finds a path forward in rare epilepsies)|
|AXO-AAV-GM1||Sio Gene Therapies||GM1 gangliosidosis||Ph1/2 12-month data from low dose cohort H2 (5 patients)||24||See text.|
|Xpovio||Karyopharm||1L maintenance endometrial cancer||Siendo Ph3 topline H2||-||Label expansion|
|Aerie||Dry eye disease||Ph2b top-line Comet-1||-||Stifel: Aerie expects AR-15512 to serve the need for immediate relief (with no pain); current therapies for chronic DED have slow onset and poor compliance.|
|Veverimer||Tricida||Chronic kidney disease||Ph3 Valor-CKD interim H2||-||Veverimer received a CRL last August, Valor-CKD was supposed to be the confirmatory post-marketing study|
|IMR-687||Imara||b-thalassemia, sickle cell||Ph2b Forte, Ph2b Ardent H2||-||Disappointed in sickle cell, Ardent is testing a higher dose (Imara disappoints in sickle cell disease)|
|*On the market already in different therapy line. Sources: Evaluate Pharma, company releases, analyst notes & clinicaltrials.gov.|